Arcellx (ACLX) Cash from Financing Activities (2021 - 2025)
Arcellx's (ACLX) quarterly Cash from Financing Activities came in at $1.6 million in Q4 2025, up 127.16% year-on-year from $719328.2 in Q4 2024, and down 98.1% quarter-over-quarter from $86.1 million in Q3 2025.
Arcellx (ACLX) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Arcellx's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.
- On a quarterly basis, Cash from Financing Activities rose 127.16% year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $98.5 million, a 509.08% increase from a year earlier, with the FY2025 full-year figure at $98.5 million, up 509.08% from the prior year.
- Cash from Financing Activities eased to $1.6 million in Q4 2025 per ACLX's latest filing, from $86.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $188.6 million in Q4 2023 and bottomed at -$10.4 million in Q2 2024.
- The 5-year median for Cash from Financing Activities is $928500.0 (2022), against an average of $36.2 million.
- Across the five-year window, Cash from Financing Activities jumped 14252.44% in 2023 and slumped 9088.79% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $15000.0 in 2021, then surged by 8660.0% to $1.3 million in 2022, then soared by 14252.44% to $188.6 million in 2023, then tumbled by 103.19% to -$6.0 million in 2024, then surged by 127.16% to $1.6 million in 2025.
- Per Business Quant, the three latest ACLX Cash from Financing Activities figures stand at $1.6 million (Q4 2025), $86.1 million (Q3 2025), and $10.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.63 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 86.10 Mn |
| Sep 30, 2025 | 86.10 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Mar 31, 2025 | 543,000.00 |
| Mar 31, 2025 | 543,000.00 |
| Dec 31, 2024 | -6.02 Mn |
| Dec 31, 2024 | -6.02 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Dec 31, 2023 | 188.59 Mn |
| Dec 31, 2023 | 188.59 Mn |
| Sep 30, 2023 | -4.99 Mn |
| Sep 30, 2023 | -4.99 Mn |